文献速递耳科与耳神经

顺铂相关听力损失与年龄相关听力损失的长期随访关系

The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up.
PubMed 文献 · Laryngoscope · 2020-02-17

结论认为顺铂耳毒性在治疗后第一个十年后无显著进展,且与年龄相关听力损失可能呈次加性效应。

要点

  • 顺铂化疗后高频听力损失常见,但长期随访中年龄调整后接近一般人群。
  • 自报听力损失问卷在长期随访中特异性下降,需结合听力检查。
  • 长期随访顺铂耳毒性应进行年龄和性别匹配。

核心结论

  • 顺铂化疗相关耳毒性导致高频听力损失,但在治疗后第一个十年之后未见显著进展。
  • 长期随访中患者听力阈值接近一般人群,可能与年龄相关听力损失呈次加性效应。

研究设计与样本

  • 听力阈值基于一般人群年龄匹配的听力阈值进行年龄调整,听力损失定义为任何频率阈值>20 dB。

主要发现

  • 两次调查间,高频听力损失(4、6、8 kHz)患病率从73%增至94%,但年龄调整后接近老龄化一般人群。
  • 首次调查时年龄>40岁的患者,后续调查中听力损失与对照组相当。
  • 自报听力损失从第一次调查的7例(9%)增至第二次调查的20例(26%)。
  • 第一次调查中,所有7例自报听力下降者均检出年龄调整后听力损失;第二次调查中,20例自报听力损失者中有7例听力阈值与对照组无差异。

临床怎么用

  • 长期随访顺铂化疗患者耳毒性时,强烈建议进行年龄和性别匹配。
  • 自报听力损失问卷在长期随访中检测耳毒性的特异性下降,应结合听力检查评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cisplatin-related hearing loss (HL) is claimed to progress after treatment. This controlled longitudinal study with extended follow-up investigates HL in testicular cancer survivors (TCSs) after cisplatin-based chemotherapy (CBCT). STUDY DESIGN: Controlled longitudinal study. METHODS: Eighty-two TCSs treated with CBCT between 1980 and 1994 in Norway participated in two surveys (S1/S3), including pure-tone audiograms (0.125-8 kHz) and self-reported HL, 12 and 31 years after treatment, respectively. Hearing thresholds were age-adjusted based on age-matched hearing thresholds from the general population (controls). Hearing loss was defined as thresholds >20 dB at any frequency. RESULTS: Between the two surveys, the prevalence of high-frequency HL (4, 6, and 8 kHz) increased from 73% to 94% but approached those of the aging general population after age adjustment. In TCSs aged >40 years at first survey, HL at the subsequent survey equaled that of controls. Self-reported HL increased from seven (9%) at S1 to 20 (26%) at S3. At S1, age-adjusted HL was identified in all (seven) TCSs reporting decreased hearing whereas at S3, hearing thresholds did not differ from controls in seven out of 20 patients reporting HL. CONCLUSION: CBCT-related ototoxicity causes high-frequency HL, but in contrast to reports from follow-up studies from the first post-treatment decade, no major progression was found beyond the first post-treatment decade for frequencies 0.125-8 kHz. Importantly, with extended follow-up, hearing thresholds of patients approach those of the general population, possibly due to a less-than-additive effect with age-related hearing loss (ARHL) in CBCT-treated patients. Age-and sex-matching is strongly advised in long-term follow-up of CBCT-related ototoxicity. Specificity for detecting ototoxicity with self-reported questionnaires decreases with extended follow-up. LEVEL OF EVIDENCE: 3 Laryngoscope, 130:E515-E523, 2020.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Skalleberg J, Småstuen MC, Oldenburg J, et al. The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up. Laryngoscope. 2020. PMID: 32065408. doi:10.1002/lary.28543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。